華大基因(300676.SZ):華大因源製造的兩項“三聯檢”產品完成CE認證
格隆匯 9 月 23日丨華大基因(300676.SZ)公佈,控股子公司深圳華大因源醫藥科技有限公司(以下簡稱華大因源)製造的兩項新型冠狀病毒、甲型流感病毒及乙型流感病毒聯合核酸檢測試劑盒(簡稱三聯檢)於近日完成了歐盟CE認證。
根據歐盟《體外診斷醫療器械指令》規定,華大因源製造的兩項“三聯檢”產品已經完成了CE申報,並得到了主管機構的確認,上述兩項檢測產品已具備歐盟市場的准入條件。
上述兩項“三聯檢”產品完成CE認證,豐富了公司感染防控業務的產品線,有利於進一步提升公司產品的國際競爭力,在全球範圍內助力新型冠狀病毒感染的肺炎疫情及流感防控工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.